Hi, I'm Tyler Sandal. I am a clinical pharmacist at the Mayo Clinic in Rochester, Minnesota. I primarily focus on treating patients with multiple myeloma and amyloidosis and other plasma cell disorders. Our research that we're presenting here at ASH this week is in the relapse refractory setting in patients receiving Ticlystumab. We looked at patients who receive commercial Ticlystumab for relapse refractory myeloma after four prior lines of therapy. And our major focus was looking at safety and efficacy or feasibility outcomes of administering in the outpatient setting. So the majority of patients undergoing step-up dosing at the Mayo Clinic do it in an outpatient setting. At the time of data cutoff, we had 49 patients with 45 patients who had completed step-up dosing at the time of cutoff. 41 of those patients did complete step-up dosing in an outpatient setting. What we found was that in terms of safety events for these patients, about 30-ish percent had cytokine release syndrome, with most cases being grade 1. We did have two patients with grade 2 CRS and one patient with grade 4 CRS. There were two cases of ICANs during our step-up dosing phase. Both of those patients were able to be treated in an inpatient setting and able to continue with therapy. In terms of time spent monitoring or in the actual clinics itself, during step-up dosing, most patients were seen for about 30-60 minutes from time of dose administration to clinic checkout. And beyond that, once they were in the maintenance dosing phase, most patients were able to be treated and checked out of the clinic in under 30 minutes. So what our data was able to show us is that outpatient administration of Toclistimab step-up dosing is both safe and feasible to be done in an outpatient setting.
HealthTree • December 19, 2023